21Shares Launches Injective ETP with Staking Features on Euronext

**21Shares Launches Staking-Enabled Injective ETP on Euronext**

In a significant development for the cryptocurrency market, 21Shares has introduced a new staking-enabled Exchange Traded Product (ETP) based on Injective Protocol (INJ) on Euronext. This product aims to provide investors with exposure to Injective Protocol while allowing them to earn staking rewards. The innovative ETP caters to the growing interest among investors in decentralized finance (DeFi) projects and staking mechanisms.

The Injective ETP stands out by enabling investors to benefit from the native staking rewards offered by INJ, thereby maximizing their potential returns. By listing on Euronext, 21Shares enhances accessibility for European investors looking to diversify their portfolios with advanced crypto products. This launch represents a forward-thinking approach to combining traditional financial instruments with the unique benefits of blockchain technology, further bridging the gap between conventional finance and the burgeoning DeFi sector.